Apolipoprotein B and Apolipopotein A-I in Vascular Risk Prediction – A Review

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|40|6289-6298

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.40, 2014-12, pp. : 6289-6298

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Apolipoprotein A-I, Phospholipid Vesicles, and Cyclodextrins as Potential Anti-Atherosclerotic Drugs: Delivery, Pharmacokinetics, and Efficacy

By Dass Crispin R.   Jessup Wendy  

Drug Delivery, Vol. 7, Iss. 3, 2000-07 ,pp. : 161-182

Informa Healthcare

Access to resources Recommend Favorite

Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain

By Zensi Anja   Begley David   Pontikis Charles   Legros Celine   Mihoreanu Larisa   Büchel Claudia   Kreuter Jörg  

Journal of Drug Targeting, Vol. 18, Iss. 10, 2010-12 ,pp. : 842-848

Informa Healthcare

Access to resources Recommend Favorite

Apolipoprotein B and apolipoprotein E genotypes and sporadic holoprosencephaly

By  

American Journal of Medical Genetics, Vol. 108, Iss. 1, 2002-02 ,pp. : 75-77

John Wiley & Sons Inc

Access to resources Recommend Favorite

Polymorphisms in the Apolipoprotein(a) Gene, Plasma Lp(a) and Cardiovascular Risk

By  

Heart Drug, Vol. 3, Iss. 4, 2004-02 ,pp. : 217-224

Karger

Access to resources Recommend Favorite

Apolipoprotein B Antisense Inhibition -Update on Mipomersen

By  

Current Pharmaceutical Design, Vol. 19, Iss. 17, 2013-05 ,pp. : 3132-3142

Bentham Science Publishers

Access to resources Recommend Favorite